Preview: New Modalities

Hot topics in automated screening and expression of new modalities: Whether antibody conjugates (ADCs or radiopharmaceuticals), T-cell, NK-cell or MAIT engagers, bispecific checkpoint inhibitors, molecular condensate inhibitors or Protac: Time-saving and error-averse automated screening and expression procedures, virtual docking, ML-based simulation and validation cycles play a key role in the drug development process. European Biotechnology Magazine, in cooperation with its official partner, the Society of Laboratory Automation & Screening, take a closer look at the relevant technologies, developers, AI tools and service providers in a special feature. Don’t miss this unique opportunity to present your service, pipeline or platform in an excellent editorial environment.